Ursodeoxycholic acid in liver diseases

Jacek Juszczyk

doi:10.5114/pg.2012.29879

eISSN: 1897-4317
ISSN: 1895-5770

Gastroenterology Review/Przegląd Gastroenterologiczny

Current issue Archive Manuscripts accepted About the journal Editorial board Abstracting and indexing Subscription Contact Instructions for authors Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2012
vol. 7

Send email

Copy url:

abstract:

Review paper

Ursodeoxycholic acid in liver diseases

Jacek Juszczyk

Prz Gastroenterol 2012; 7 (3): 138–142

DOI: https://doi.org/10.5114/pg.2012.29879

Online publish date: 2012/08/14

View full text Get citation

PlumX metrics:

Ursodeoxycholic acid (UDCA) has for several years been used for the treatment of primary biliary cirrhosis (PBC). In PBC it is the only drug approved by the United States Food and Drug Administration, and recommended by the American Association for the Study of Liver Disease and the European Association for the Study of the Liver. Use of UDCA in patients with primary sclerosing hepatitis has been associated with improvements in serum liver tests and often also histological and clinical findings. Non-alcoholic fatty liver disease is the most common form of chronic hepatitis. Ursodeoxycholic acid showed in some studies beneficial effects on activity of aminotransferase as well as histopathological changes in the liver, but in another one no such improvement was observed. The best results were obtained with a higher dose of UDCA, and in combination with other drugs.

keywords:

Ursodeoxycholic acid in liver diseases

Jacek Juszczyk

ursodeoxycholic acid, primary biliary cirrhosis, non-alcoholic fatty liver diseases